This study, called EUCLID, is looking at how radiation therapy for lung or esophageal cancer might affect your heart. Sometimes, radiation can reach the heart, potentially changing how it works. Doctors don't fully understand these changes or how to best detect them. This study uses a special type of scan called a sarcoidosis fludeoxyglucose F-18 (FDG) PET-CT (positron emission tomography-computed tomography) to look for these changes in the heart. Researchers want to see if these imaging changes can help predict overall survival, heart-related problems, or even death. You might be able to join if you are at least 18 years old, have lung or esophageal cancer, and are expected to live at least 3 months. The study aims to enroll 20 participants.

Study design

This is an interventional study, meaning participants will receive specific procedures. It is not specified if it's randomized or blinded, and it plans to enroll 20 participants.

What's involved

You would undergo sarcoidosis FDG PET-CT scans of your heart before, during, and after radiation therapy. You will also complete questionnaires.

Compensation

Not stated in the trial record.

Follow-up

After completing study treatment, participants will have follow-up visits at 12 and 24 months. The primary endpoint is measured up to 30 months after radiotherapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.